Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors
- 1 October 2011
- journal article
- research article
- Published by Springer Nature in Investigational New Drugs
- Vol. 30 (5) , 1950-1957
Abstract
Summary Panobinostat (LBH589) is a potent pan-histone deacetylase inhibitor. As a result of promising preclinical data, Phase I and II clinical trials of intravenous and oral panobinostat have been conducted in patients with a wide variety of hematologic and solid tumors. This is the first report of a phase I study to evaluate intravenous panobinostat given on days 1 and 8 of a 21-day cycle in patients with solid tumors. The primary objective was to characterize the safety and tolerability of panobinostat by evaluating the occurrence of dose-limiting toxicity (DLT) and determining the maximum tolerated dose (MTD) in Japanese patients with advanced solid tumors. Secondary objectives included characterizing the pharmacokinetics and assessing antitumor activity. Fourteen patients were assigned to three dose levels (Cohort 1: 10 mg/m2 [three patients], Cohort 2: 15 mg/m2 [three patients], Cohort 3: 20 mg/m2 [eight patients]), according to a standard “3 + 3” design. One patient who received 20 mg/m2 had a DLT (grade 3 elevation of γ-glutamyl transpeptidase for >7 days). Thrombocytopenia was observed in all patients (grade 3 or 4 in 8), the severity of which was dependent on the dose and platelet count at baseline. The thrombocytopenia rapidly resolved within 8 days. Plasma panobinostat levels increased dose dependently, without clinically significant drug accumulation. Stable disease for ≥4 months was observed in six patients; however, there were no complete or partial responses. It is feasible to conclude that 20 mg/m2 was the MTD and recommend as the starting dose for phase II clinical trials.Keywords
This publication has 15 references indexed in Scilit:
- A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumorsInvestigational New Drugs, 2011
- Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytesLeukemia, 2010
- Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group StudyJournal of Clinical Oncology, 2010
- Histone Deacetylase Inhibitors in Cancer TherapyJournal of Clinical Oncology, 2009
- Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challengesCancer Letters, 2009
- EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiationProceedings of the National Academy of Sciences, 2009
- The many roles of histone deacetylases in development and physiology: implications for disease and therapyNature Reviews Genetics, 2009
- EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's SarcomaPLOS ONE, 2008
- Antitumor effects of histone deacetylase inhibitor on Ewing's family tumorsInternational Journal of Cancer, 2005
- Identification of p21 as a Direct Target of EWS-Fli1 Oncogenic Fusion ProteinJournal of Biological Chemistry, 2003